WATERTOWN, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended September 30, 2016, and highlighted recent clinical development achievements in antibiotics pipeline.
“The third quarter was one of meaningful progress for Tetraphase and our phase 3 eravacycline program,” said Guy Macdonald, Tetraphase’s President and Chief Executive Officer. “We successfully initiated IGNITE4 evaluating twice-daily intravenous (IV) eravacycline in patients with complicated intra-abdominal infections (cIAI) and announced dosing of the first patient in October. Top-line results from IGNITE4 are expected as early as the fourth quarter of 2017. We also continue to prepare for the initiation of IGNITE3, our planned phase 3 trial exploring once-daily IV eravacycline in complicated urinary tract infections (cUTI).”
